Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Pieris Pharmaceuticals Inc. (PIRS)

3.6   0.38 (11.8%) 05-29 16:00
Open: 3.18 Pre. Close: 3.22
High: 3.6389 Low: 3.15
Volume: 614,790 Market Cap: 188M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.534 - 3.553 3.553 - 3.569
Low: 3.149 - 3.169 3.169 - 3.185
Close: 3.188 - 3.221 3.221 - 3.249

Technical analysis

as of: 2020-05-29 3:59:13 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 4.20     One year: 4.91
Support: Support1: 2.80    Support2: 2.30
Resistance: Resistance1: 3.60    Resistance2: 4.20
Pivot: 3.06
Moving Average: MA(5): 3.31     MA(20): 2.93
MA(100): 2.98     MA(250): 3.69
MACD: MACD(12,26): 0.19     Signal(9): 0.13
Stochastic oscillator: %K(14,3): 87.51     %D(3): 88.92
RSI: RSI(14): 64.63
52-week: High: 6.04  Low: 1.60  Change(%): -15.3
Average Vol(K): 3-Month: 46875  10-Days: 37230

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
PIRS has closed above the upper band by 4.4%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 6.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Mon, 11 May 2020
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

Mon, 11 May 2020
Pieris Pharmaceuticals: 1Q Earnings Snapshot - San Francisco Chronicle

Mon, 11 May 2020
Pieris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update - Yahoo Finance

Thu, 14 May 2020
Earnings Update: Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance

Mon, 04 May 2020
Pieris Pharmaceuticals to Host First Quarter 2020 Investor Call and Corporate Update on May 11, 2020 - Yahoo Finance

Thu, 28 May 2020
Pieris Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference - Yahoo Finance

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 52
Shares Float (M) 41
% Held by Insiders 0.22
% Held by Institutions 71.82
Shares Short (K) 1,790
Shares Short P. Month (K) 1,760

Stock Financials

EPS -0.417
EPS Est This Year -0.850
EPS Est Next Year -0.950
Book Value (p.s.) 0.900
Profit Margin -36.71
Operating Margin -39.87
Return on Assets (ttm) -10.0
Return on Equity (ttm) -46.8
Qtrly Rev. Growth 55.2
Gross Profit (p.s.) 0.885
Sales Per Share 0.975
EBITDA (p.s.) -0.373
Qtrly Earnings Growth
Operating Cash Flow (M) -52
Levered Free Cash Flow (M) -30

Stock Valuations

PE Ratio -8.55
PEG Ratio
Price to Book value 3.96
Price to Sales 3.66
Price to Cash Flow -3.55

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.